MusthInsider

Latest On Cabaletta Bio, Inc (CABA):

Updated on: March 19, 2021

Date/Time	Type	Description	Signal
2023-05-18 16:00 EST	News	Cabaletta Bio up 1%, prices $87M offering	N/A
2023-05-18 02:29 EST	News	Cabaletta Bio commences underwritten public offering of shares	N/A
2023-05-16 23:33 EST	News	Cabaletta Bio jumps 16% as FDA clears trial for myositis candidate	N/A
2023-05-11 15:27 EST	News	Cabaletta Bio GAAP EPS of -$0.45 beats by $0.02	N/A
2023-05-01 18:20 EST	News	Cabaletta's potential lupus drug CABA-201 gets FDA fast track tag	N/A
2023-04-28 03:16 EST	News	Cabaletta Bio: Speculative Biotech With Opportunity	N/A
2023-03-31 16:02 EST	News	Cabaletta CAR T cell therapy for lupus gets FDA nod to enter trial	N/A
2023-03-31 16:02 EST	News	4 stocks to watch on Friday: Amazon, Kraft Heinz, and more	N/A
2023-03-16 13:19 EST	News	Cabaletta Bio GAAP EPS of -$0.52 misses by $0.08	N/A
2023-01-27 17:59 EST	News	Cabaletta rises as Morgan Stanley upgrades citing new CAR-T asset	N/A
2023-01-25 12:46 EST	News	Cabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)	N/A
2022-12-08 20:30 EST	News	Cabaletta Bio dips on announcing $35M offering	N/A
2022-11-10 11:40 EST	News	Cabaletta Bio GAAP EPS of -$0.39 beats by $0.09	N/A
2022-08-30 16:03 EST	News	Cabaletta downgraded at Morgan Stanley on upcoming data for lead asset	N/A
2022-08-11 21:46 EST	News	Cabaletta Bio GAAP EPS of -$0.45 beats by $0.05	N/A
2022-05-18 20:14 EST	News	Cabaletta Bio updates Phase 1 interim data for lead asset	N/A
2022-05-12 11:04 EST	News	Cabaletta Bio GAAP EPS of -$0.45	N/A
2022-03-18 09:46 EST	News	Cabaletta Bio GAAP EPS of -$0.49 beats by $0.11	N/A
2021-12-14 08:41 EST	News	Cabaletta Bio tanks 34% on cell therapy data in early-stage study for pemphigus vulgaris	N/A
2021-11-01 14:01 EST	News	Cabaletta Bio EPS beats by $0.05	N/A
2021-11-01 14:01 EST	News	Cabaletta rises as skin diseases drug shown to be safe in early data of phase 1 trial	N/A
2021-08-19 00:00 EST	News	Cabaletta Bio reports results from DesCAARTes trial in patients with pemphigus vulgaris	N/A
2021-08-05 20:25 EST	News	Cabaletta Bio EPS beats by $0.03	N/A
2021-03-18 15:25 EST	Analyst Rating	The Analyst Target Price has increased from $20.33 to $22.25.	Buy
2021-03-18 07:46 EST	Financials	Company financials have been released.	Neutral
2021-03-17 17:01 EST	News	Cabaletta Bio EPS misses by $0.04	N/A
2021-03-17 15:39 EST	Earnings Estimate	An EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.	Sell
2021-03-17 15:39 EST	Earnings Estimate	An EPS average of -$2.18 is estimated for the 2022 year.	Sell
2021-01-20 12:58 EST	News	Cabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young Biotech	N/A
2021-01-11 10:22 EST	Analyst Rating	The Analyst Target Price has increased from $20 to $20.33.	Buy
2021-01-09 03:37 EST	News	Chardan Capital initiates Cabaletta Bio with Buy rating	N/A
2020-12-10 06:47 EST	News	Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder	N/A
2020-12-04 06:26 EST	Financials	Company financials have been released.	Neutral
2020-11-27 00:46 EST	Financials	Company financials have been released.	Neutral
2020-11-24 15:51 EST	Analyst Rating	The Analyst Target Price has decreased from $21.67 to $20.	Neutral
2020-11-17 07:28 EST	Financials	Company financials have been released.	Neutral
2020-11-14 23:46 EST	Financials	Company financials have been released.	Neutral
2020-11-12 07:15 EST	Financials	Company financials have been released.	Neutral
2020-11-11 09:52 EST	News	Cabaletta Bio EPS beats by $0.08	N/A
2020-11-11 09:52 EST	News	Cabaletta Bio +5% on Q3 results, pipeline update	N/A
2020-11-11 06:54 EST	Earnings Estimate	An EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.	Sell
2020-10-15 08:02 EST	News	Cabaletta Bio (CABA) Investor Presentation - Slideshow	N/A
2020-10-14 11:22 EST	Analyst Rating	The Analyst Target Price has decreased from $22.5 to $21.67.	Neutral
2020-10-08 21:07 EST	Financials	Company financials have been released.	Neutral
2020-10-04 15:25 EST	Financials	Company financials have been released.	Neutral
2020-09-26 16:38 EST	Financials	Company financials have been released.	Neutral
2020-09-17 09:18 EST	Financials	Company financials have been released.	Neutral
2020-08-14 12:44 EST	Financials	Company financials have been released.	Neutral
2020-08-10 03:29 EST	Financials	Company financials have been released.	Neutral
2020-08-07 23:40 EST	Financials	Company financials have been released.	Neutral

About Cabaletta Bio, Inc (CABA):

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.

See Advanced Chart

General

Name Cabaletta Bio, Inc
Symbol CABA
Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
SectorHealthcare
IndustryBiotechnology
Full Time Employees 31
Fiscal Year EndDecember
IPO Date2019-10-25
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Web URLhttp://www.cabalettabio.com

Valuation

Price/Book (Most Recent Quarter) 2.23

Financials

Most Recent Quarter 2020-12-31
Current Year EPS Estimate -$2.13
Next Year EPS Estimate -$2.45
Next Quarter EPS Estimate -$0.42
Return on Assets -17%
Return on Equity -27%
Earnings Per Share -$0.94
Revenue Per Share $0
Quarterly Earnings Growth 0%

Highlights

Market Capitalization 276.24 million
Analyst Target Price $22.25

Share Statistics

Shares Outstanding 24.06 million
Shares Float 7.91 million
% Held by Insiders 523%
% Held by Institutions 67.4%
Shares Short 1.63 million
Shares Short Prior Month 1.61 million
Short Ratio 15.52
Short % of Float 8%
Short % of Shares Outstanding 7%

Technicals

52 Week High $16.38
52 Week Low $6.07
50 Day Moving Average 11.96
200 Day Moving Average 12.4

Dividends

Dividend Date N/A
ExDividend Date N/A
Dividend Yield 0%

Cabaletta Bio, Inc (CABA) Dividend Calendar:

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount

Cabaletta Bio, Inc (CABA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-12-31	2021-03-16	$N/A	-$0.40	-$0.36	-11.11%
2020-09-30	2020-11-10	$N/A	-$0.36	-$0.44	18.18%
2020-06-30	2020-08-06	$N/A	-$0.35	-$0.39	10.26%
2020-03-31	2020-05-12	$N/A	-$0.33	-$0.23	-43.48%
2019-12-31	2020-03-30	$N/A	-$0.33	-$0.47	29.79%
2019-09-30	2019-12-05	$N/A	-$1.21	-$2.26	46.46%

Cabaletta Bio, Inc (CABA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date	Dec 31 2020	Sep 30 2020	Jun 30 2020	Mar 31 2020	Dec 31 2019
Research Development	5.78 million	N/A	N/A	4.62 million	3.03 million
Income Before Tax	-9.31 million	N/A	N/A	-7.49 million	-5.4 million
Selling General Administrative	3.56 million	N/A	N/A	3.28 million	2.83 million
Gross Profit	N/A	N/A	N/A	N/A	N/A
Ebit	-9.22 million	N/A	N/A	-7.82 million	-5.81 million
Operating Income	-9.33 million	N/A	N/A	-7.9 million	-5.86 million
Income Tax Expense	N/A	N/A	N/A	N/A	N/A
Total Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Total Other Income Expense Net	N/A	N/A	N/A	N/A	N/A
Net Income From Continuing Operations	-9.31 million	N/A	N/A	-7.49 million	-5.4 million
Net Income Applicable to Common Shares	-9.31 million	-8.39 million	-8.15 million	N/A	-5.4 million

Cash Flow:

Date	Sep 30 2020	Jun 30 2020	Mar 31 2020	Dec 31 2019	Sep 30 2019
Investments	1.47 million	N/A	-226000	-273000	-40000
Change to Liabilities	N/A	-978000	N/A	-306000	672000
Total Cash Flow from Investing Activities	N/A	-11.12 million	N/A	-273000	-40000
Net Borrowings	N/A	N/A	N/A	N/A	N/A
Total Cash Flow from Financial Activities	135000	N/A	-44000	73.32 million	-2.1 million
Change to Operating Activities	N/A	315000	N/A	-3.04 million	1.3 million
Change in Cash	-3.42 million	N/A	-5.2 million	65.16 million	-4.22 million
Total Cash from Operating Activities	-5.02 million	-7.64 million	-4.93 million	-7.88 million	-2.08 million
Depreciation	90000	N/A	76000	51000	32000
Other Cash Flow from Investing Activities	N/A	N/A	N/A	N/A	N/A
Change to Inventory	N/A	N/A	N/A	N/A	N/A
Change to Account Receivables	N/A	N/A	N/A	N/A	N/A
Other Cash Flow from Financing Activities	N/A	-147000	N/A	2.1 million	-2.1 million
Change to Net Income	N/A	1.1 million	N/A	819000	569000
Capital Expenditures	162000	N/A	226000	273000	40000

Balance Sheet:

Date	Dec 31 2020	Sep 30 2020	Jun 30 2020	Mar 31 2020	Dec 31 2019
Total Liabailities	5.18 million	4.27 million	N/A	3.26 million	3.15 million
Total Stockholder Equity	109.54 million	117.51 million	N/A	131.71 million	138.32 million
Other Current Liabilities	38000	140000	N/A	101000	177000
Total Assets	114.72 million	121.77 million	N/A	134.97 million	141.47 million
Common Stock	N/A	N/A	N/A	N/A	N/A
Other Current Assets	1.85 million	N/A	N/A	N/A	N/A
Retained Earnings	-66.3 million	-56.99 million	-48.6 million	-40.44 million	-32.96 million
Other Liabilities	N/A	N/A	N/A	N/A	N/A
Other Assets	299000	N/A	238000	N/A	101000
Cash	101.43 million	108.68 million	N/A	131 million	136.2 million
Total Current Liabilities	5.18 million	4.27 million	N/A	3.26 million	3.15 million
Other Stockholder Equity	6000	N/A	11000	N/A	N/A
Property, Plant & Equipment	890000	N/A	806000	N/A	815000
Total Current Assets	113.54 million	119.22 million	N/A	134.12 million	140.55 million
Long Term Investments	N/A	1.33 million	N/A	N/A	N/A
Net Tangible Assets	109.54 million	N/A	124.64 million	N/A	138.32 million
Short Term Investments	7.23 million	8.06 million	N/A	N/A	N/A
Long Term Debt	N/A	N/A	N/A	N/A	N/A
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Payable	1.24 million	953000	N/A	1.99 million	920000

Cabaletta Bio, Inc (CABA) Chart:

Cabaletta Bio, Inc (CABA) News:

Below you will find a list of latest news for Cabaletta Bio, Inc (CABA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cabaletta Bio, Inc (CABA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date:

Options Type:

Moneyness:

Expiration Date	Strike	Last Price	Type	Volume	Open Interest	Implied Volatility	In The Money	Change	Change Percent
2025-06-20	0.5	0	CALL	0	2	1214.32	TRUE	0	0
2025-06-20	1	0.9	CALL	0	22	429.72	TRUE	0	0
2025-06-20	1.5	0.7	CALL	6	180	123.19	TRUE	0.2	0.4
2025-06-20	2	0.3	CALL	5	397	108.39	TRUE	0.15	1
2025-06-20	2.5	0.18	CALL	115	233	156.29	FALSE	0.04	0.29
2025-06-20	5	0.05	CALL	0	225	219.71	FALSE	0	0
2025-06-20	7.5	0	CALL	0	0	0	FALSE	0	0
2025-06-20	0.5	0	PUT	0	0	445.33	FALSE	0	0
2025-06-20	1	0.05	PUT	0	22	248.66	FALSE	0	0
2025-06-20	1.5	0.11	PUT	0	38	193.69	FALSE	0	0
2025-06-20	2	0.1	PUT	6	79	98.62	FALSE	0.1	0
2025-06-20	2.5	0	PUT	0	0	185.82	TRUE	0	0
2025-06-20	5	0	PUT	0	0	330.86	TRUE	0	0
2025-06-20	7.5	0	PUT	0	0	423.37	TRUE	0	0
2025-07-18	0.5	0	CALL	0	0	312.42	TRUE	0	0
2025-07-18	1	0	CALL	0	0	390.28	TRUE	0	0
2025-07-18	1.5	0	CALL	0	12	288.53	TRUE	0	0
2025-07-18	2	0.4	CALL	0	89	137.52	TRUE	0	0
2025-07-18	2.5	0.17	CALL	0	39	85.11	FALSE	0	0
2025-07-18	5	0	CALL	0	12	171.33	FALSE	0	0
2025-07-18	7.5	0	CALL	0	1	1320.82	FALSE	0	0
2025-07-18	0.5	0	PUT	0	0	868.29	FALSE	0	0
2025-07-18	1	0	PUT	0	0	434.03	FALSE	0	0
2025-07-18	1.5	0	PUT	0	4	331.16	FALSE	0	0
2025-07-18	2	2.58	PUT	0	71	124.95	FALSE	0	0
2025-07-18	2.5	0	PUT	0	0	64.43	TRUE	0	0
2025-07-18	5	0	PUT	0	0	761.04	TRUE	0	0
2025-07-18	7.5	0	PUT	0	0	819	TRUE	0	0
2025-08-15	0.5	0	CALL	0	7	667.51	TRUE	0	0
2025-08-15	1	0	CALL	0	38	154.15	TRUE	0	0
2025-08-15	1.5	0.9	CALL	51	294	149.83	TRUE	0.1	0.13
2025-08-15	2	0	CALL	0	128	135.49	TRUE	0	0
2025-08-15	2.5	0.5	CALL	0	288	85.93	FALSE	0	0
2025-08-15	5	0.05	CALL	0	1396	134.16	FALSE	0	0
2025-08-15	7.5	0	CALL	0	287	160.98	FALSE	0	0
2025-08-15	0.5	0	PUT	0	20	215.78	FALSE	0	0
2025-08-15	1	0	PUT	0	8	417.9	FALSE	0	0
2025-08-15	1.5	0	PUT	0	30	156.52	FALSE	0	0
2025-08-15	2	0	PUT	0	4	113.04	FALSE	0	0
2025-08-15	2.5	0	PUT	0	17	92.11	TRUE	0	0
2025-08-15	5	0	PUT	0	196	239.44	TRUE	0	0
2025-08-15	7.5	0	PUT	0	2	167.9	TRUE	0	0
2025-11-21	0.5	1.7	CALL	5	58	117.96	TRUE	1.7	0
2025-11-21	1	0	CALL	0	24	140.76	TRUE	0	0
2025-11-21	1.5	0	CALL	0	70	126.77	TRUE	0	0
2025-11-21	2	0.8	CALL	20	204	124.87	TRUE	0	0
2025-11-21	2.5	0.68	CALL	7	1291	132.3	FALSE	0.06	0.1
2025-11-21	5	0.3	CALL	16	831	135.57	FALSE	0.06	0.25
2025-11-21	7.5	0.15	CALL	101	1249	180.11	FALSE	0.15	0
2025-11-21	0.5	0	PUT	0	0	0	FALSE	0	0
2025-11-21	1	0	PUT	0	14	197.22	FALSE	0	0
2025-11-21	1.5	0	PUT	0	51	116.44	FALSE	0	0
2025-11-21	2	0	PUT	0	38	168.52	FALSE	0	0
2025-11-21	2.5	0.97	PUT	2	351	134.74	TRUE	0.97	0
2025-11-21	5	0	PUT	0	41	183.7	TRUE	0	0
2025-11-21	7.5	0	PUT	0	1	215.57	TRUE	0	0

Latest CABA Trades:

Date	Shares	Price
Jun 13, 2022 7:37 PM EST	1	$1.08
Jun 13, 2022 7:37 PM EST	6	$1.08
Jun 13, 2022 7:51 PM EST	7	$1.06
Jun 13, 2022 7:57 PM EST	7	$1.06
Jun 13, 2022 7:58 PM EST	7	$1.055

Cabaletta Bio, Inc (CABA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Form Type:

Date	Form Type	Form Name	Link
2020-06-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2019-10-24	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319025941/0000899243-19-025941-index.htm
2019-10-24	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319025942/0000899243-19-025942-index.htm
2019-10-24	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319025943/0000899243-19-025943-index.htm
2019-10-24	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319025946/0000899243-19-025946-index.htm
2019-10-24	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319025947/0000899243-19-025947-index.htm
2019-10-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319026016/0000899243-19-026016-index.htm
2019-10-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319026017/0000899243-19-026017-index.htm
2019-10-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319026018/0000899243-19-026018-index.htm
2019-10-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319026020/0000899243-19-026020-index.htm
2019-10-30	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319026345/0000899243-19-026345-index.htm
2019-10-30	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924319026346/0000899243-19-026346-index.htm
2020-02-13	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924320004509/0000899243-20-004509-index.htm
2020-02-13	5	Annual statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924320004511/0000899243-20-004511-index.htm
2020-03-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924320006864/0000899243-20-006864-index.htm
2020-03-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924320006865/0000899243-20-006865-index.htm
2020-03-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924320006867/0000899243-20-006867-index.htm
2020-09-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000089924320025326/0000899243-20-025326-index.htm
2020-07-21	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1759138/000090266420002724/0000902664-20-002724-index.htm
2019-11-07	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1759138/000092963819000988/0000929638-19-000988-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1759138/000092963820000331/0000929638-20-000331-index.htm
2019-10-24	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000110465919056233/0001104659-19-056233-index.htm
2019-10-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000110465919057348/0001104659-19-057348-index.htm
2019-10-31	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-11-12	SC 13D	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1759138/000110465919061822/0001104659-19-061822-index.htm
2019-10-24	S-1MEF	Registration adding securities to prior Form S-1 registration [Rule 462(b)]	https://www.sec.gov/Archives/edgar/data/1759138/000119312519273939/0001193125-19-273939-index.htm
2019-10-25	424B4	Prospectus [Rule 424(b)(4)]	https://www.sec.gov/Archives/edgar/data/1759138/000119312519274807/0001193125-19-274807-index.htm
2019-10-29	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1759138/000119312519277804/0001193125-19-277804-index.htm
2019-10-30	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312519278927/0001193125-19-278927-index.htm
2019-11-07	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1759138/000119312519287367/0001193125-19-287367-index.htm
2020-01-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312520005110/0001193125-20-005110-index.htm
2020-01-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312520017724/0001193125-20-017724-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1759138/000119312520038349/0001193125-20-038349-index.htm
2020-02-20	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312520042689/0001193125-20-042689-index.htm
2020-03-30	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312520090013/0001193125-20-090013-index.htm
2020-03-30	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1759138/000119312520091086/0001193125-20-091086-index.htm
2020-04-23	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1759138/000119312520115863/0001193125-20-115863-index.htm
2020-05-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312520134391/0001193125-20-134391-index.htm
2020-05-12	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312520139782/0001193125-20-139782-index.htm
2020-05-28	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/0001193125-20-153792-index.htm
2020-06-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2020-08-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1759138/000119312520211336/0001193125-20-211336-index.htm
2019-10-30	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1759138/000119380519001374/0001193805-19-001374-index.htm
2019-10-30	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm
2020-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1759138/000119380520000185/0001193805-20-000185-index.htm
2019-12-05	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1759138/000156459019045375/0001564590-19-045375-index.htm
2020-03-30	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1759138/000156459020013929/0001564590-20-013929-index.htm
2020-05-12	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1759138/000156459020024508/0001564590-20-024508-index.htm
2020-08-06	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1759138/000156459020037278/0001564590-20-037278-index.htm
2019-10-24	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1759138/999999999519002384/9999999995-19-002384-index.htm

Cabaletta Bio, Inc (CABA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cabaletta Bio, Inc (CABA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 523%
Institutional Ownership: 6740%

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction	Link
2019-10-29	5AM Ventures V, L.P.	10% Share Holder	Buy	454,545.00	11.00	4,999,995.00	454,545.00	https://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-10-29	James E Flynn	10% Share Holder	Buy	700,000.00	11.00	7,700,000.00	700,000.00	https://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm

Cabaletta Bio, Inc

(NASDAQ:CABA)